期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CD258(LIGHT)在肿瘤免疫治疗中的研究进展 被引量：4

下载PDF
导出
摘要 CD258(LIGHT)即肿瘤坏死因子超家族成员14(TNFSF14),能够与其功能性受体单纯疱疹病毒侵入介体(HVEM)、淋巴毒素β受体(LTβR)结合,在体内、体外均可发挥明显的抗肿瘤效应。CD258介导的信号通路在不同肿瘤细胞系中表现出复杂的促凋亡机制,并且在不同的肿瘤细胞系中表现出促进和抑制肿瘤生长的双重作用。随着免疫学及分子生物学技术的发展,促进了CD258在肿瘤免疫治疗中的研究和应用。现对CD258在肿瘤免疫治疗中的机制和应用的新进展进行综述。
作者 李权 李涛 李瑞鹏 刘建河
机构地区 上海交通大学医学院附属新华医院泌尿外科
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2016年第1期118-121,共4页 Chinese Journal of Cellular and Molecular Immunology
关键词 CD258(肿瘤坏死因子超家族成员14) 肿瘤 免疫治疗 综述
分类号 R730.3 [医药卫生—肿瘤] G353.11 [文化科学—情报学]
  • 相关文献

参考文献2

二级参考文献20

  • 1Granger SW, Butrovich KD, Houshmand P, et al. Genomic characterization of LIGHT reveals linkage to an immune response locus on chro- mosome 19p13. 3 and distinct isoforms generated by alternate splicing or proteolysis[ J]. J Immunol, 2001, 167(11) : 5122 -5128.
  • 2Vincenti F. Costimulation blockade in autoimmunity and transplantation[J]. J Allergy Clin Immunol, 2008, 121(2) : 299 -306.
  • 3Kroczek R, Hamelmann E. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies[ J ]. J Allergy CIin Immunol, 2005, 116 (4) : 9006 -9009.
  • 4Bodmer JL, Sehneider P, Tschopp J. The molecular architecture of the TNF superfamily[ J]. Trends Biochem Sei, 2002, 27( 1 ) : 19 -26.
  • 5Tamada K, Shimozaki K, Chapoval AI, et al. LIGHT, a TNF like molecule, eostimulates T cell proliferation and is required for dendritic eell-medlated altogeneie T cell response [ J ]. J Immunol, 2000, 164 (8) : 4105 -4110.
  • 6Del Rio ML, Lucas CL, Buhler L, et al. HVEM/LIGHT/BTLA/ CD160 cosigualing pathways as targets for immune regulation[J]. J Leukoc Biol, 2010, 87(2) : 223 -225.
  • 7Rooney IA, Butrovich KD, Glass AA, et al. The lymphotoxin-beta re- ceptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells[ J]. J Bid Chem, 2000, 275(19) : 14307 - 14315.
  • 8Tarnada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell- mediated immunity in tumor and graft-versus-host disease models through the LIGHT costimulatory pathway [ J]. Nat Med, 2000, 6 (3) : 283 -289.
  • 9Granger SW, Rickert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity[ J]. Cytokine Growth Factor Rev, 2003, 14 (34) : 289 - 296.
  • 10Ishida S, Yamane S, Ochi T, et al. LIGHT induces cell proliferation and inflammatory responses of rheumatoid arthritis synovial fibroblasts via lymphotoxin beta receptor [ J ]. J Rhemnatol, 2008, 35 (6) : 960 - 968.

共引文献7

同被引文献32

  • 1Cohen JI. Epstein-barr virus vaccines[J]. Clin Transl Immunology, 2015, 4(1):e32.
  • 2Thompson MP, Kurzrock R. Epstein-barr virus and vancer[J]. Clin Cancer Res, 2004,10(3) :803-821.
  • 3Rowe M, Lear AL, Croom-Carter D, et al. Three pathways of epstein-barr virus gene activation from EBNAl-positive latency in B lymphocytes[J]. J Virol, 1992,66 (1) : 122-131.
  • 4Sivachandran N, Wang X, Frappier L. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection[J]. J Viro1,2012, 86( 11 ) :6146-6158.
  • 5Jiang W, Chen R, Kong X, et al. Immunization with adenovirus LIGHT- engineered dendritic ceils induces potent T cell responses and therapeutic immunity in HBV transgenic mice [J]. Vaccine, 2014,32 (35) : 4565-4570.
  • 6Kanodia S, Da Silva DM, Karamanukyan T,et al. Expression of LIGHT/ TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression[J]. Cancer Res, 2010,70 (10) : 3955-3964.
  • 7Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines : prospects for success[J]. Curr Opin Immunol, 2011,23 (3) :421-429.
  • 8Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses[J]. Proc Natl Acad Sci USA, 1999, 96 (8) : 4262-4267.
  • 9Tamada K, Shimozaki K, Chapoval AI, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response[J]. J Immunol, 2000,164 (8) : 4105-4110.
  • 10Zhai Y, Guo R, Hsu TL, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer[J]. J Clin Invest, 1998,102 (6) : 1142-1151.

引证文献4

二级引证文献1

细胞与分子免疫学杂志
2016年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部